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Background: This study was performed to assess the 2006 introduced ENETS TNM-classification with respect to
patient survival and surgical approach for patients who underwent surgery for a neuroendocrine tumor of the
pancreas (PNET).
Methods: Between 2001 and 2010 38 patients after resection of a PNET were investigated regarding tumor
localization and size. Further, patient survival with regards to the new TNM-classification, the operation methods
and immunohistochemical markers was analyzed.
Results: The estimated mean survival time of the 38 patients was 91 ± 10 months (female 116 ± 9, male 56 ± 14 months;
p = 0.008). The 5-year survival rate was 63.9%. Patient survival differed significantly depending on tumor size (pT1
107 ± 13, pT2 94 ± 16, pT3 44 ± 7 and pT4 18 ± 14 months; P = 0.006). Patients without lymph node metastasis
survived significantly longer compared to patients with positive lymph node status (108 ± 9 vs. 19 ± 5 months;
P < 0.001). However, survival in patients with and without distant metastasis did not differ significantly (92 ± 11 vs.
80 ± 23 months; P = 0.876). Further, the tumor grading significantly influenced patient survival (G1 111 ± 12, G2
68 ± 12 and G3 21 ± 14 months; P = 0.037).
Conclusions: As part of the TNM-classification especially lymph node status and also tumor size and grading
were identified as important factors determining patient survival. Further, gender was demonstrated to significantly
influence survival time. If an R0 resection was achieved in patients with distant metastases patient survival was
comparable to patients without metastasis.
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Neuroendocrine tumors represent a heterogenous group
of neoplasms regarding biological features and clinical be-
havior [1-3]. These tumors are rare with an incidence be-
tween 3.24 and 6.5 per 100,000 [4]. However, over the last
years there has been a remarkable increase in frequency
with predominant localization of the neuroendocrine tu-
mors in the gastrointestinal tract or the bronchopulmon-
ary system [4]. Approximately 5% of all neuroendocrine
tumors develop in the pancreas with one of the poorest
outcomes (35% 5-year survival rate) [3,5-8]. The WHO
classification published in 2000 and modified by Kloeppel
at al. in 2004 distinguishes between well-differentiated
neuroendocrine tumors, well-differentiated neuroendo-
crine carcinomas and poorly-differentiated neuroendo-
crine carcinomas [7]. Because of the wide variety in
clinical behavior between these tumor entities, a tailored
surgical and medical therapy based on this classification
was challenging [9]. A new TNM classification with a
grading system based on the mitotic count and the Ki-67
index was established by the European Neuroendocrine
Tumor Society (ENETS) to address this problem in 2006.
In this system PNETs with a size <2 cm are classified as
T1, with a size from 2–4 cm as T2, with >4 cm or invasion
of duodenum or bile duct as T3, and all tumors invading
adjacent organs or the wall of large vessels as T4 [10]. The
status of regional lymph nodes and distant metastasis were
taken into account analogously to the TNM classification
system of other tumors in combination with a grading
system according to mitotic count and the Ki-67-index.
Based on these criteria, a risk stratification of patients
using different disease stages was proposed. Stage I in-
cludes pT1 tumors, stage IIa pT2 tumors, stage IIb pT3
tumors and stage IIIa pT4 tumors all without lymph node
or distant metastasis. Tumors of any pT stage with lymph
node metastasis are classified in stage IIIb and all tumors
with distant metastasis are characterized as stage IV [10].
In 2010 the UICC/AJCC/WHO 2010 TNM staging system
was introduced which differs significantly from the 2006
ENETS TNM staging. Due to the fact that Rindi et al.
demonstrated that the 2006 ENETS TNM staging system
is superior to the UICC/AJCC/WHO 2010 TNM staging
system we decided to use the 2006 ENETS TNM staging
for our study [11]. Since the 2006 ENETS TNM classifica-
tion is based on the published experience of single centers
and not on a uniform database, the purpose of this study
was to analyze neuroendocrine tumors of the pancreas
that were resected in our center with regards to clinico-
pathological characteristics that influence patient survival.
Further, we wanted to assess the new 2006 ENETS TNM
classification system and its prognostic value for long-
term survival.
Additionally to Ki-67 that as marker for proliferation
is included in the TNM classification systems it has beenshown previously that pancreatic endocrine neoplasms
and adenocarcinoma of the pancreas express E-cadherin
and β-catenin, both being important for cell-cell contact,
and that cyclin D1 and IL-17A contribute to malignant
transformation in pancreatic tumors [12-17]. In our
study we tested if different expression levels of these
markers influence patient survival.
Methods
Study setting
The study was performed at the University Medical Cen-
ter of Regensburg, Germany in the Department of Surgery
in compliance with the Helsinki Declaration and was ap-
proved by the ethics committee of the University Medical
Center Regensburg, Germany (Nr. 13-180-0248).
Study cohort
Patients with PNETs confirmed by histology who under-
went surgery at our center between 2001 and 2010 were
identified using the hospital computer data base (access
available with permission of the University Medical Center
Regensburg, Germany). Only patients with a surgically
possible R0 resection were included (N = 38). If a distant
metastasis was present these metastases were resected
simultaneously which was achieved in 6 out of the 7 pa-
tients with distant metastases. General patient information
like age and gender were documented. Tumor localization
was categorized as pancreas head, corpus or tail based on
intraoperative findings and histology. Partial pancreato-
duodenectomy (Kausch-Whipple operation), pancreas tail
resection with and without splenectomy and localized re-
section were used as operation methods, individually
adapted for tumor size, localization and extent of tumor
infiltration into other organs. In case of a localized resec-
tion a systematic lymphadenectomy was only performed
in case of suspicious lymph nodes in the preoperative
diagnostic. Survival data were obtained using the database
of the regional tumor center of East Bavaria, Germany
(access freely available for hospitals in the region of East
Bavaria, Germany). Two patients were lost to follow-up
and were excluded from the survival analysis.
Histology
The specimens were fixed in 4% paraformaldehyde and
embedded in paraffin. The tumor tissue sections were ree-
valuated by a pathologist based on the 2006 ENETS TNM
classification [10]. Additionally, tissue sections from the
tumor region were also stained for endocrine markers and
the proliferation marker Ki-67 and a mitotic count was
conducted for each specimen. Therefore, positive nuclear
staining (MIB-1 antibody) in 10 subsequent high power
fields in areas with highest proliferative activity was
counted. Further, immunohistochemistry of tissue micro-
array sections was performed. 2 μm tissue microarray
Table 1 General characteristics of patients with PNETs
Female Male p
N 20(52.6%) 18(47.4%)
Age at operation (years) 54±16 50±16 0.400
Tumor size (cm) 3.2±3.6 3.7±2.8 0.596
Tumor localization 0.621
Pancreas head 5 7
Pancreas corpus 5 3
Pancreas tail 10 8
pT Stage 0.164
pT1 8 5
pT2 8 4
pT3 2 7
pT4 1 2
Nodal Status 0.095
NO 17 11
N1 3 7
Metastasis 0.024
cMO 19 12 *
cM1 1 6 *
Grading 0.023
G1 13 5 *
G2 6 10 *
G3 0 3 *
Age and tumor size presented as mean±SD.Group comparisons using the
Mann-White-U-test or persons’s chi-squared test (*p<0.05).
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for cyclin D1 (RM-9104-R7, NeoMarkers Inc., Fremont, CA,
USA; Dilution 1:25), E-cadherin (M3612, Dako North
America Inc., Carpinteria, CA, USA; Dilution 1:50), β-
catenin (sc-7963, Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA; Dilution 1:50) and IL-17A (AF-317-
NA, R&D Systems Inc. Minneapolis, MN, USA; Dilu-
tion 1:50) with a Ventana BenchMark Ultra IHC/ISH
Staining Module (Ventana Medical Systems, Inc., Tucson,
Arizona, USA) according to the manufacturers staining
procedures. Stained tissue microarrays were analyzed by an
independent pathologist blinded for patient and survival
data. E-cadherin and β-catenin expression was quantified
in 3 levels as low, intermediate and high, cyclin D1 and IL-
17A expression was described in 2 levels as low or high.
Statistics
For statistical analysis SPSS 18.0 for Windows (Copy-
right SPSS Inc., Chicago, Illinois, USA) was used. The
distribution of age at operation, follow-up period, tumor
size and operation time was described as mean ± stand-
ard deviation and compared using Mann–Whitney-U-
test due to the fact that these values do not show a nor-
mal distribution. Survival after surgery was estimated
using the Kaplan-Meier method. The log rank test was
used to compare survival stratified according to histo-
logical classification and grading, tumor localization, op-
eration method, age at operation, gender and different
immunohistochemical groups. Distributions of tumor
stages, nodal status, metastasis, grading and operation
methods were analyzed with Pearsons’s chi squared test.
P values < 0.05 were considered statistically significant.Results
General characteristics
In total 38 patients (18 men, 20 women) with PNETs were
included in this retrospective analysis. The mean follow-up
time was 45 months. Among the 38 PNETs, twelve neo-
plasms (31.6%) were localized in the pancreas head, eight
(21.1%) in the pancreas corpus and eighteen (47.4%) in the
pancreas tail. Eight patients (21.1%) had a functional (3
glucagonomas, 5 insulinomas) and thirty patients (78.9%) a
non-functional PNET. Two patients were lost during
follow-up and were excluded from survival analysis. Out of
the 36 persons who completed follow-up, ten (27.8%) died
during this period. The mean age at operation did not sig-
nificantly differ between women and men (54 ± 16 vs. 50 ±
16 years). The mean tumor size was 3.5 ± 0.5 cm (range
0.3 – 15.0 cm; women 3.2 ± 3.6 vs. 3.7 ± 2.8 cm) (Table 1).
TNM classification
According to the TNM classification, 13 of the PNETs
were staged as pT1 (34%), 12 as pT2 (32%), 9 as pT3 (24%)and 3 as pT4 (8%) with no statistically significant difference
in gender distribution. In one patient there was not enough
material left for a histological reevaluation of the tumor.
Therefore, this patient was excluded from the analysis re-
garding T stages and grading. 28 of the patients (74%) had
a negative lymph node status whereas in 10 patients (26%)
the lymph nodes were infiltrated by tumor cells. Though
there was a trend towards increased lymph node infiltra-
tion in male patient the level of significance was not
reached. Distant metastases were present in seven patients
(18%) with a statistically significant higher ratio of men
(P = 0.024), in the remaining 31 patients (82%) no metasta-
sis were found. Eighteen of the 37 PNETs were graded as
G1 (47%), 16 as G2 (42%) and 3 as G3 (8%) tumors with a
statistically significant higher tumor grading in male
patients (P = 0.023). (Additional file 1: Table S1; detailed
TNM staging of individual patients in Additional file 1:
Table S1).
Operation methods
Eight patients (21%) were treated with a localized resec-
tion either as enucleation of the tumor or as pancreas
segment resection. Five patients (13%) received a spleen
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(37%) had a pancreas tail resection with splenectomy
and in eleven patients (29%) a partial pancreatoduode-
nectomy (Kausch-Whipple operation) was performed.
For a tumor localization in the pancreas head only in 1
out of 12 patients (8%) a localized resection was used
compared to a higher rate of a limited surgical approach
in the pancreas corpus (3 out of 8 localized resections;
38%) and in the pancreas tail (4 out of 18 localized re-
sections (22%) and 5 out of 18 (28%) spleen preserving
pancreas tail resections.Gender but not tumor localization influences patient
survival
Survival curves were calculated using the Kaplan-Meier
method. The mean overall survival time was 91 ±
10 months and the 5-year overall survival rate was 64%.
Women had an estimated mean survival time of 116 ±
9 months which was significantly longer compared to
men with 56 ± 14 months (P = 0.008) (Figure 1).
The mean survival time for PNETs localized in the
pancreas head was 49 ± 9 months, in the pancreas cor-
pus 70 ± 18 months and in the pancreas tail 105 ±
12 months without significant differences.Figure 1 Overall survival and survival stratified for gender. The mean overa
was 63.9%. Women showed a significantly longer mean survival time compT stage, nodal status and grading but not distant
metastasis influence survival of resected patients
Further, the influence of the tumor size on patient sur-
vival after resection of the PNETs was assessed. In this
analysis pT1 tumors showed a mean survival of 107 ±
13 months, pT2 tumors of 94 ± 16 months, pT3 tumors
of 44 ± 7 months and pT4 tumors of 18 ± 14 months.
Survival of pT1, pT2 and pT3 stages was statistically sig-
nificant different to survival of patients with pT4 tumors
(pT1 vs. pT4 P = 0.001; pT2 vs. pT4 P = 0.026; pT3 vs.
pT4 P = 0.047) (Figure 2A).
Additionally, the influence of the lymph node status
on patient survival was tested using the Kaplan-Meier
method. Patients with negative lymph node status had a
statistically significant longer estimated mean survival
time of 108 ± 9 months compared to patients with tumor
infiltrated lymph nodes with an estimated mean survival
time of 19 ± 5 months (P < 0.001) (Figure 2B).
Furthermore, a survival analysis with regards to distant
metastasis was performed. Interestingly, mean survival
time of cM1 tumors (N = 7) was not significantly differ-
ent compared to cM0 tumors (N = 31) (80 ± 23 months
vs. 92 ± 11 months; P = 0.876) (Figure 3A). Notably,
within the patients that developed distant metastases the
distribution of tumor grading (2 G1, 4 G2, 1 G3) wasll survival time was 92 ± 10 months and the 5-year overall survival rate
ared to men (116 ± 9 versus 56 ± 14 months; P = 0.008).
Figure 2 Patient survival stratified for pT stages and lymph node status. (A) The survival of pT1 tumors (N = 13; 107 ± 13 months), pT2 tumors
(N = 12; 94 ± 16 months), pT3 tumors (N = 9; 44 ± 7 months) and pT4 tumors (N = 3; 18 ± 14 months) differed significantly (pT1 vs. pT2 P = 0.485;
pT1 vs. pT3 P = 0.266; pT1 vs. pT4 P = 0.001; pT2 vs. pT3 P = 0.862; pT2 vs. pT4 P = 0.026; pT3 vs. pT4 P = 0.047). (B) N0 (N = 28) tumors showed
significant longer survival time compared to N1 (N = 10) tumors (108 ± 9 versus 19 ± 5 months; P < 0.001).
Figure 3 Patient survival stratified for distant metastasis and grading. (A) Survival time of patients without metastasis (N = 31) was statistically not
different to patients with distant metastases (N = 7) (92 ± 11 versus 80 ± 23 months; P = 0.876). (B) The survival of patients with G1 tumors (N = 18;
111 ± 12 months), G2 tumors (N = 16; 68 ± 12 months) and G3 tumors (N = 3; 21 ± 14 months) differed significantly (G1 vs. G2 P = 0.126; G1 vs. G3
P = 0.022; G2 vs. G3 P = 0.127).
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(16 G1, 12 G2, 2 G3; P = 0.471).
Next, the influence of tumor grading on patient survival
was investigated. Patients with a PNET histologically clas-
sified as G1 had a mean survival time of 111 ± 12 months,
compared to 68 ± 12 months for patients with a G2 tumor
and 21 ± 14 months when the tumor was classified as G3.
The difference in patient survival between G1 and G3 tu-
mors was statistically significant (G1 vs. G2 P = 0.126; G1
vs. G3 P = 0.022; G2 vs. G3 P = 0.127) (Figure 3B).
Finally, survival analysis using the disease staging pro-
posed by the new TNM classification revealed that pa-
tients with a stage IIIb PNET showed significantly
shorter survival (12 ± 5 months; P < 0.001) compared to
patients in stage I, IIa, IIb, IIIa and IV (I 117.38 ± 10.87;
IIa 74.12 ± 9.24; IIb 49.00 ± 0; IIIa 46.00 ± 0 months; IV
80.30 ± 23.35 months). Between stage I, IIa, IIb, IIIa and
IV no significant difference was found (Figure 4).
Intratumoral expression of cell adhesion proteins
E-cadherin and β-catenin and expression of cyclin D1
and IL-17A do not influence patient survival
To test if E-cadherin, β-catenin, cyclin D1 and IL-17A in-
fluence patient survival, these markers were additionallyFigure 4 Patient survival stratified for disease stages. Patients with stage III
compared to patients in stage I (117 ± 11 months), IIa (74 ± 9 months), IIb (
stage I, IIa, IIb, IIIa and IV no statistically significant difference could be founused to stain the PNET tissue samples. Kaplan-Meier
analysis was performed for the respective immunohisto-
chemical staining.
Low (67 ± 21 months), intermediate (91 ± 16 months)
and high intratumoral expression levels of the adhesion
protein E-cadherin (82 ± 16 months) did not show signifi-
cant differences in patient survival (P = 0.855) (Figure 5A).
Also, low (70 ± 18 months), intermediate (97 ± 16 months)
and high intratumoral expression levels of β-catenin (77 ±
16 months) revealed no significant differences in patient
survival (P = 0.795) (Figure 5B).
Patient survival with low (86 ± 11 months) and high
(92 ± 15 months) expression levels of Cyclin D1 in the tu-
mors was not significantly different (P = 0.795) (Figure 6A).
Further, the analysis of patients with low intratumoral ex-
pression levels of IL-17A (87 ± 14 months) showed a trend
to reduced survival times compared to patients with high
intratumoral IL-17A expression (117 ± 11 months) though
the difference was not statistically significant (P = 0.211)
(Figure 6B).
Discussion
In this study the lymph node status was detected to be an
important and statistically significant factor for patientb disease showed significant shorter survival (12 ± 5 months; P < 0.001)
49 ± 0 months), IIIa (46 ± 0 months) and IV (80 ± 23 months). Between
d.
Figure 5 Patient survival stratified for intratumoral E-cadherin and β-catenin expression. (A) There was no statistically significant survival difference
between patients with low (N = 9), intermediate (N = 15) and high (N = 13) expression levels of E-cadherin (67 ± 21 versus 91 ± 16 versus 82 ±
16 months; P = 0.855). (B) No statistically significant survival differences were noted for patients with low (N = 12), intermediate (N = 13) and high
(N = 12) expression levels of β-catenin (70 ± 18 versus 97 ± 16 versus 77 ± 16 months; P = 0.795).
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time of 108 ± 9 months for N0 in contrast to 19 ± 5 months
for N1 tumors (P < 0.001). This is supported by reports
from Ito and Scarpa et al. who both also identified lymph
node metastasis as relevant prognostic factor [9,18]. How-
ever, a large study with 3851 patients by Bilimoria et al.
using the National Cancer Data Base found the nodal sta-
tus not to be associated with survival [19]. A possible ex-
planation for these contrary findings may be the use of
different surgical approaches in these studies and also the
rather long time of patient recruitment between 1985 and
2004 in the epidemiologic study by Bilimoria et al. Similar
to previously published results, in this study the pT staging
and grading provided a statistically significant prognostic
stratification of patients [9,18,20].
Different to other tumor entities, in our study distant
metastasis had no impact on patient survival. This is
supported by the study of Fischer et al. who also found
no statistical influence of distant metastasis on survival
[2]. However, Scarpa et al. observed distant metastasis to
be a statistically significant factor for survival [9]. These
contrary findings may be explained by very divergingpatient cohorts and low number of cases in our study,
which is one limitation of this study additionally to the
fact that data were analyzed retrospectively at a single-
center. However, these critical result of our study can be
explained since in the study by Scarpa et al. also pallia-
tive patients without resection were included whereas in
ours and Fischer’s study only patients with surgical re-
section of the tumor were analyzed [2,9]. Taken together,
these results suggest that distant metastasis may have no
impact on patient survival if they are properly resected.
As a consequence of the findings that positive lymph
nodes but not distant metastasis influence survival of
resected patients, we were not able to get a good sur-
vival stratification using the proposed 2006 ENETS
TNM stages which stands in contrast to other studies
[10,18]. Only patients suffering from stage IIIb tumors
showed significantly worse survival in our analysis. Also
the modified staging system proposed by Scarpa et al.
would not result in a better risk stratification in our pa-
tient cohort [9]. However, this most probable is due to
low case numbers in our study since a large study by
Rindi et al. demonstrated that this ENETS TNM stages
Figure 6 Patient survival stratified for intratumoral Cyclin D1 and IL-17A expression. (A) No statistically significant survival difference was noted
between patients with low (N=20) and high (N=17) expression of Cyclin D1 (86 ± 11 versus 92 ± 15 months; P=0.795). (B) There was a trend to
reduced patient survival time in case of low (N=22) intratumoral IL-17A expression compared to high (N=15) IL-17A expression though the difference
was not statistically significant (87 ± 14 versus 117 ± 11 months; P=0.211).
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WHO 2010 TNM staging system [11].
Very interesting was the fact, that we found statisti-
cally significant differences in survival between women
and men (116 ± 9 months vs. 56 ± 14 months; P = 0.008).
This is supported by a recent study from Kim et al. who
found gender to be a prognostic factor for disease free
survival of neuroendocrine tumors and also by Rindi
et al. who also shows male patients being at higher risk
[11,21]. One reason for shorter survival of male patients
may be the trend to more tumor positive lymph nodes
and the higher tumor grading in our patient cohort,
however, these differences between men and women
were not statistically significant and therefore both
groups were comparable. Possible explanations for these
differences in tumor biology and survival may be gender
imbalances for risk factors like smoking and alcohol, a
different constitution or hormonal influences as sug-
gested by Kim et al. [21].Since previous studies demonstrated that pancreatic
endocrine neoplasms and adenocarcinoma of the pancreas
express E-cadherin and β-catenin and that further cyclin
D1 and IL-17A contribute to malignant transformation in
pancreatic tumors, these markers were used to stain
PNET tissue samples [12-17]. Cell adhesion proteins like
E-cadherin and β-catenin have also been shown to pro-
mote tumor progression and are associated with poor
patient survival in colorectal adenocarcinoma and in a
subgroup of patients with non-small cell lung cancer if
expressed at low levels [22-25]. However, no influence on
patient survival was found in our PNET cohort. Further,
no correlation of Cyclin D1 with patient survival was
shown in the investigated PNETs in contrast to other re-
ports with different tumor entities before [26,27]. In the
analysis of intratumoral IL-17A expression a trend to-
wards reduced patient survival in case of low IL-17A ex-
pression was noted, however, the differences were not
statistically significant. So far, there have been conflicting
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microenvironment on survival [28-31]. In our cohort of
PNET patients the patient number might be too small to
conclude if intratumoral IL-17A expression is beneficial.
Also, the other tested factors were not suitable for patient
risk stratification.
The surgical approach in this study was based on the in-
dividual preoperative diagnostic results with the goal to
achieve an R0 resection. Limited tumors with regards to
TNM staging and grading were treated with a localized re-
section or a pancreas tail resection without splenectomy.
If distant metastasis were present, a simultaneous resec-
tion was performed. This operation strategy is supported
by reports from Hodul et al. and others [3,32,33]. Accord-
ing to published results, we found an overall 5-year sur-
vival rate of 63.9% [9,18,19].
Taking into account that we detected the lymph node
status and the tumor grading to be the essential histo-
pathological prognostic factors for survival of patients
with surgically resected PNETs it seems to be very import-
ant to identify these patients at high risk before surgery.
For this purpose, the 68Ga-DOTATOC positron emission
tomography/computed tomography may emerge as a use-
ful tool not only for the evaluation of the primary tumor
and the distant metastasis but also for the detection of
lymph node metastasis as suggested by Kumar et al. [34].
Then an individualized surgical therapy could be per-
formed. If an extensive lymph node dissection with the
goal of achieving an R0 situation or a neoadjuvant therapy
concept with 99Y-Dotatoc as suggested by Stoelzing et al.
can improve the poor outcome of these patients needs to
be evaluated in future studies [34,35].
Conclusion
In conclusion, we identified the lymph node status and
also tumor size and grading as important survival factors
within the new ENET classification system but not dis-
tant metastasis if an R0 resection was achieved. This is
important for a tailored therapy of patients with PNETs.
Additional file
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